Status:
ACTIVE_NOT_RECRUITING
Rare Group Problem Management Plus
Lead Sponsor:
Children's National Research Institute
Collaborating Sponsors:
Travere Therapeutics, Inc.
Conditions:
Anxiety
Depressive Symptoms
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
Participants are being asked to be in the study if they are the parent or legal guardian of a child (\>1 year or \<18 years old) with a rare condition. The group based psychoeducational intervention ...
Detailed Description
Participants are being asked to be in the study because they are the parent or legal guardian of a child (infancy up to 21 years old) with a rare condition. The group based psychoeducational interven...
Eligibility Criteria
Inclusion
- • Family caregiver aged 18 years or older of a child with a rare disease from infancy to age 21 years.
- Understands and speaks English or Spanish. Reading or health literacy is not required.
- Signed consent.
- Signed waiver of assent for child.
Exclusion
- Family caregiver is under the age of 18 years.
- Child with the rare disease is over the age of 21 years.
- Family caregiver is actively suicidal, homicidal, or psychotic.
- Family caregiver is impaired (cognitively or by drugs or alcohol).
- Family caregiver has a low level of distress.
Key Trial Info
Start Date :
February 5 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2025
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT06548022
Start Date
February 5 2024
End Date
November 30 2025
Last Update
July 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's National Hospital
Washington D.C., District of Columbia, United States, 20010